9月3日 - ** 药物开发商Aptevo Therapeutics的股价在盘前交易中下跌21.2%，至2.05美元
** 该公司表示 (link)，其实验性白血病治疗药物米普他米格（mipletamig）在一项早期至中期临床试验中，对伴有TP53突变的一线急性髓系白血病（AML）患者达到了93%的临床获益率，而这类患者群通常难以治疗
** 在14名接受米普他米格联合维奈托克和阿扎胞苷治疗且可评估的TP53突变型AML患者中，有13名获得了临床获益
** 11名患者（占79%）达到了完全缓解或伴有血液学恢复不完全的完全缓解，其中包括9例完全缓解
** 与其他类型的血液癌症相比，TP53突变型AML预后较差，且反应率较低
** 去年，Aptevo报告称该试验早期队列的缓解率达100% (link)
** Aptevo预计将于年底前完成该研究的剂量优化阶段，并计划于2027年上半年开展监管讨论
** 截至上个交易日收盘，该股年内累计跌幅达72.4%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.